Graft-Versus-Host Disease
Allogeneic CAR T-cell therapy safe, clinically active in metastatic colorectal cancer
An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.
Sitagliptin may prevent acute GVHD after peripheral blood stem cell transplantation
Sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to phase 2 study results published in The New England Journal of Medicine.
Belumosudil shows promise for chronic GVHD
Belumosudil conferred high overall response rates at two dose levels among patients with chronic graft-versus-host disease, according to results of the phase 2 ROCKstar study presented at the virtual ASH Annual Meeting and Exposition.
Ruxolitinib effective as second-line therapy for chronic GVHD
Ruxolitinib conferred a higher overall response rate than best available therapy for certain patients with chronic graft-versus-host disease, according to results of an analysis presented at the virtual ASH Annual Meeting and Exposition.
FDA seeks more data about cell therapy for pediatric GVHD
The FDA issued a complete response letter to a biologics license application that seeks approval of remestemcel-L to treat certain children with graft-versus-host disease.
Antithymocyte globulin reduces acute GVHD incidence after matched sibling donor transplant
Antithymocyte globulin decreased incidence of acute graft-versus-host-disease after allogeneic stem cell transplantation from an HLA-matched sibling donor, according to randomized study results published in Journal of Clinical Oncology.
FDA panel supports Ryoncil cell therapy for children with acute GVHD
An FDA advisory committee voted 9-1 in favor of approval of the cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.
Ruxolitinib improves response, failure-free survival in chronic GVHD
A randomized phase 3 study designed to evaluate ruxolitinib for chronic graft-versus-host disease met its primary and key secondary endpoints.
Off-the-shelf CAR T-cell therapy effective for advanced T-cell acute lymphoblastic leukemia
TruUCAR GC027 — a gene edited, investigational allogeneic chimeric antigen receptor T-cell therapy — showed efficacy for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to preliminary results of a first-in-human phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.
Ruxolitinib effective, safe for glucocorticoid-refractory acute GVHD
Ruxolitinib appeared to be more effective than common treatments for patients with glucocorticoid-refractory acute graft-versus-host-disease, according to results of a randomized phase 3 study published in The New England Journal of Medicine.